-
Je něco špatně v tomto záznamu ?
Omega-3 fatty acids and cardiovascular disease risk: do we understand the relationship?
M. Vrablík, M. Prusíková, M. Šnejdrlová, L. Zlatohlávek
Jazyk angličtina Země Česko
Typ dokumentu přehledy
NLK
Directory of Open Access Journals
od 1991
Free Medical Journals
od 1998
ProQuest Central
od 2005-01-01
Medline Complete (EBSCOhost)
od 2006-01-01
Nursing & Allied Health Database (ProQuest)
od 2005-01-01
Health & Medicine (ProQuest)
od 2005-01-01
ROAD: Directory of Open Access Scholarly Resources
od 1998
- MeSH
- financování organizované MeSH
- hodnocení rizik MeSH
- kardiovaskulární nemoci etiologie metabolismus prevence a kontrola MeSH
- klinické zkoušky jako téma MeSH
- kyseliny mastné omega-3 aplikace a dávkování metabolismus MeSH
- lidé MeSH
- medicína založená na důkazech MeSH
- potravní doplňky MeSH
- rizikové faktory MeSH
- výživová politika MeSH
- Check Tag
- lidé MeSH
- Publikační typ
- přehledy MeSH
There is a large body of evidence documenting the effects of long-chain polyunsaturated fatty acids with the first double bond at the third position from methyl-terminal (so called omega-3 fatty acids (FAs)) on different components of cardiovascular disease (CVD) risk. However, it may seem the more answers on the topic we learn, the more questions remain to be elucidated. There are three levels of evidence documenting the impact of fish omega-3 FAs on CVD risk. Epidemiological data have shown unequivocally the increased intake of fish is associated with lower CVD morbidity and mortality. Numerous experimental studies have shown (almost always) positive effects of omega-3 FAs on lipoprotein metabolism, coagulation and platelet function, endothelial function, arterial stiffness etc. Most importantly, there are a few prospective clinical endpoint trials (DART, JELIS, GISSI Prevenzione and GISSI-HF) that have examined the impact of omega-3 FAs supplementation on cardiovascular outcomes in different patient populations. Recent meta-analyses of these and other clinical studies have yielded somewhat conflicting results. In this review we will summarize current evidence of omega-3 FAs effects on cardiovascular risk focusing on new data from recent clinical trials as well as possible practical implications for clinical practice.
Citace poskytuje Crossref.org
Lit.: 37
- 000
- 00000naa 2200000 a 4500
- 001
- bmc09002081
- 003
- CZ-PrNML
- 005
- 20151006140732.0
- 008
- 091103s2009 xr e eng||
- 009
- AR
- 024 7_
- $a 10.33549/physiolres.931860 $2 doi
- 040 __
- $a ABA008 $b cze $c ABA008 $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xr
- 100 1_
- $a Vrablík, Michal, $d 1973- $7 xx0061419
- 245 10
- $a Omega-3 fatty acids and cardiovascular disease risk: do we understand the relationship? / $c M. Vrablík, M. Prusíková, M. Šnejdrlová, L. Zlatohlávek
- 314 __
- $a Third Department of Internal Medicine, First Medical Faculty of Charles University and General University Hospital, Prague
- 504 __
- $a Lit.: 37
- 520 9_
- $a There is a large body of evidence documenting the effects of long-chain polyunsaturated fatty acids with the first double bond at the third position from methyl-terminal (so called omega-3 fatty acids (FAs)) on different components of cardiovascular disease (CVD) risk. However, it may seem the more answers on the topic we learn, the more questions remain to be elucidated. There are three levels of evidence documenting the impact of fish omega-3 FAs on CVD risk. Epidemiological data have shown unequivocally the increased intake of fish is associated with lower CVD morbidity and mortality. Numerous experimental studies have shown (almost always) positive effects of omega-3 FAs on lipoprotein metabolism, coagulation and platelet function, endothelial function, arterial stiffness etc. Most importantly, there are a few prospective clinical endpoint trials (DART, JELIS, GISSI Prevenzione and GISSI-HF) that have examined the impact of omega-3 FAs supplementation on cardiovascular outcomes in different patient populations. Recent meta-analyses of these and other clinical studies have yielded somewhat conflicting results. In this review we will summarize current evidence of omega-3 FAs effects on cardiovascular risk focusing on new data from recent clinical trials as well as possible practical implications for clinical practice.
- 650 _2
- $a financování organizované $7 D005381
- 650 _2
- $a kardiovaskulární nemoci $x etiologie $x metabolismus $x prevence a kontrola $7 D002318
- 650 _2
- $a klinické zkoušky jako téma $7 D002986
- 650 _2
- $a potravní doplňky $7 D019587
- 650 _2
- $a medicína založená na důkazech $7 D019317
- 650 _2
- $a kyseliny mastné omega-3 $x aplikace a dávkování $x metabolismus $7 D015525
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a výživová politika $7 D018673
- 650 _2
- $a hodnocení rizik $7 D018570
- 650 _2
- $a rizikové faktory $7 D012307
- 655 _2
- $a přehledy $7 D016454
- 700 1_
- $a Vaclová, Martina $7 xx0160828
- 700 1_
- $a Šnejdrlová, Michaela $7 jx20070921020
- 700 1_
- $a Zlatohlávek, Lukáš $7 xx0061418
- 773 0_
- $w MED00003824 $t Physiological research $g Roč. 58,Suppl. 1 (2009), s. S19-S26 $x 0862-8408
- 773 0_
- $t Nutrition - integral part of the treatment of the important diseases $x 0862-8408 $g Roč. 58,Suppl. 1 (2009), s. S19-S26 $w MED00173856
- 856 41
- $u http://www.biomed.cas.cz/physiolres/pdf/58%20Suppl%201/58_S19.pdf $y plný text volně přístupný
- 910 __
- $a ABA008 $b A 4120 $c 266 $y 8 $z 0
- 990 __
- $a 20091103075056 $b ABA008
- 991 __
- $a 20151006140917 $b ABA008
- 999 __
- $a ok $b bmc $g 691251 $s 553149
- BAS __
- $a 3
- BMC __
- $a 2009 $b 58 $c Suppl. 1 $d S19-S26 $i 0862-8408 $m Physiological research $x MED00003824
- BMC __
- $a 2009 $b 58 $c Suppl. 1 $d S19-S26 $i 0862-8408 $m Nutrition - integral part of the treatment of the important diseases $x MED00173856
- LZP __
- $a 2009-51/ipme